Accelerates Growth Strategy by Adding Two Mid- to Late-Stage Product Candidates: Pelabresib (CPI-0610) and CPI-0209 Bolsters Position in Hematology-Oncology and Expands into Solid Tumors Best-in-Class
Investegate announcements from MorphoSys AG, MorphoSys AG to Acquire Constellation Pharmaceuticals and Enter into Strategic Funding Partnership with Royalty Pharma
MorphoSys AG to Acquire Constellation Pharmaceuticals and Enter into Strategic Funding Partnership with Royalty Pharma
MUNICH, GERMANY and CAMBRIDGE, MA / ACCESSWIRE / June 2, 2021 / MorphoSys AG (FSE:MOR) (NASDAQ:MOR) ( MorphoSys ), announces today that it has entered into a definitive agreement with Constellation Pharmaceuticals, Inc. (NASDAQ: CNST) ( Constellation ) whereby MorphoSys will acquire Constellation for $34.00 per share in cash, which represents a total equity value of $1.7 billion. The transaction has been unanimously approved by the Management Board (
Vorstand) and the Supervisory Board (
Aufsichtsrat) of MorphoSys, as well as the Board of Directors of Constellation and is expected to close in the third quarter of 2021.
Kinder Morgan has agreed to acquire a Consolidated Edison-Crestwood JV.
Kinder Morgan, Inc. (NYSE: KMI) reported Tuesday that it has agreed to acquire Stagecoach Gas Services LLC for a purchase price of $1.225 billion.
A joint venture between Consolidated Edison, Inc. (NYSE: ED) and Crestwood Energy Partners LP (NYSE: CEQP), Stagecoach comprises four natural gas storage facilities and three pipelines serving U.S. Northeast market demand and Marcellus supply, Kinder Morgan noted in a written statement.
“Acquiring Stagecoach will enhance our service to customers in this part of the country,” remarked Kimberly S. Watson, president of KMI’s Interstate Natural Gas Pipelines unit. “These natural gas pipeline and storage facilities help connect natural gas supply sources and Northeast demand areas.”
MorphoSys has agreed to acquire Constellation Pharmaceuticals for $1.7 billion cash, the companies said today, in a deal that grows the buyer’s presence in blood cancer treatments and expands it into solid tumors.